Ortin Global Ltd Stock Price Today (NSE: ORTINGLOBE)
Fundamental Score
Ortin Global Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ortin Global Ltd share price today is ₹17.30, up +1.88% on NSE/BSE as of 17 June 2026. Ortin Global Ltd (ORTINGLOBE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.59 (Cr). The 52-week high for ORTINGLOBE share price is ₹19.90 and the 52-week low is ₹10.66. The company has a Return on Equity (ROE) of -36.25% and a debt-to-equity ratio of 0.72.
Ortin Global Ltd Share Price Chart — NSE/BSE Historical Performance
Ortin Global Ltd share price chart: 7.51% return over the past month. 52-week high ₹19.90, 52-week low ₹10.66.
Ortin Global Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹15.01 | ₹15.75 | ₹15.01 | ₹15.74 | 2.25K (Cr) | |
| ₹16.20 | ₹16.20 | ₹15.01 | ₹15.01 | 1.08K (Cr) | |
| ₹17.10 | ₹17.12 | ₹15.50 | ₹15.51 | 49.24K (Cr) | |
| ₹16.00 | ₹16.31 | ₹16.00 | ₹16.31 | 21.98K (Cr) | |
| ₹15.50 | ₹16.29 | ₹15.50 | ₹15.54 | 3.10K (Cr) | |
| ₹14.57 | ₹16.09 | ₹14.57 | ₹15.70 | 11.48K (Cr) | |
| ₹14.82 | ₹16.14 | ₹14.82 | ₹15.33 | 1.90K (Cr) | |
| ₹15.75 | ₹15.75 | ₹14.30 | ₹15.60 | 2.66K (Cr) | |
| ₹15.40 | ₹15.54 | ₹15.00 | ₹15.00 | 13.70K (Cr) | |
| ₹14.80 | ₹14.80 | ₹14.73 | ₹14.80 | 2.29K (Cr) |
Ortin Global Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹16.20 | ₹16.20 | ₹15.01 | ₹15.74 | -2.84% | |
| ₹15.50 | ₹17.12 | ₹13.50 | ₹15.51 | +0.06% | |
| ₹14.23 | ₹16.19 | ₹13.62 | ₹15.50 | +8.92% | |
| ₹17.30 | ₹17.40 | ₹13.50 | ₹13.56 | -21.62% | |
| ₹12.98 | ₹19.90 | ₹11.51 | ₹17.19 | +32.43% | |
| ₹13.80 | ₹14.35 | ₹11.90 | ₹12.47 | -9.64% | |
| ₹11.85 | ₹17.46 | ₹11.65 | ₹13.81 | +16.54% | |
| ₹10.91 | ₹12.89 | ₹10.83 | ₹11.96 | +9.62% | |
| ₹11.42 | ₹12.89 | ₹10.66 | ₹11.25 | -1.49% | |
| ₹13.13 | ₹13.15 | ₹11.17 | ₹11.42 | -13.02% | |
| ₹15.60 | ₹18.93 | ₹11.55 | ₹13.40 | -14.10% | |
| ₹11.98 | ₹14.86 | ₹10.86 | ₹14.86 | +24.04% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ortin Global Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ortin Global Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ORTINGLOBE across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Cash Generation (₹26.61 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (-36.25%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-25.11%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-12.65%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-80.00%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-71.99% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Stagnant Profit Growth (-16.00% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-95.00x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Low Promoter Commitment (1.23%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 1.68%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ortin Global Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ortin Global Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ortin Global LtdOrtin Global Lt...Selected✓ ORTINGLOBE • 539287 | 0/100 | ₹17.30₹17 | ₹10.59₹10.59 | — — | -36.25%Poor -36.25% Poor | -25.11%Poor -25.11% Poor | 0.72Good 0.7 Good | -16.00%Poor -16.00% Poor | -71.99%Poor -71.99% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Ortin Global Ltd Quarterly Performance
Latest quarterly metrics for ORTINGLOBE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-80.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-6.38%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-71.99%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-16.00%
Compounded annual net profit growth over 5 years
Ortin Global Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ORTINGLOBE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ortin Global Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ortin Global Ltd (ORTINGLOBE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ortin Global Ltd
About ORTINGLOBE (Ortin Global Ltd)
Ortin Global Ltd is a pioneering pharmaceutical company dedicated to the advancement of healthcare through the development, production, and distribution of high-quality medicines. ...With a firm commitment to innovation and patient well-being, Ortin Global strives to address unmet medical needs across a spectrum of therapeutic areas. Driven by a team of experienced scientists and professionals, the company focuses on creating effective and accessible pharmaceutical solutions, while upholding the highest standards of quality and ethical conduct. Ortin Global envisions a world where advanced healthcare is readily available to all, and it pursues this goal with unwavering dedication and a spirit of continuous improvement. Ortin Global’s core business revolves around the creation and manufacturing of a diverse portfolio of pharmaceutical formulations, encompassing a wide range of therapeutic categories. The company produces tablets, capsules, syrups, and dry powders, each meticulously crafted to meet stringent quality control standards. Ortin Global's product offerings include medications for managing chronic conditions like diabetes, allergies, and cardiovascular ailments, as well as treatments for infectious diseases, pain relief, and mental health. The company's commitment to innovation extends to constantly exploring new drug delivery systems and formulations that enhance patient compliance and improve therapeutic outcomes. Ortin Global is deeply rooted in a culture of quality, safety, and ethical business practices. The company adheres to the highest global regulatory standards and maintains state-of-the-art manufacturing facilities to ensure the purity, potency, and efficacy of its products. With a firm belief in corporate social responsibility, Ortin Global actively engages in initiatives that promote health awareness, environmental sustainability, and community development. As a trusted pharmaceutical company, Ortin Global remains steadfast in its mission to provide innovative and affordable healthcare solutions, enriching the lives of patients around the globe.
Company Details
Key Leadership
ORTINGLOBE Share Price: Frequently Asked Questions
What is the current share price of Ortin Global Ltd?
Ortin Global Ltd (ORTINGLOBE) trades at ₹17.30 on NSE and BSE. Market cap ₹10.59 (Cr). Educational data only.
What is the P/E ratio of Ortin Global Ltd?
Ortin Global Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Ortin Global Ltd?
Ortin Global Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Ortin Global Ltd pay dividends?
Ortin Global Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ortin Global Ltd?
Ortin Global Ltd has ROE of -36.25%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ortin Global Ltd?
Ortin Global Ltd has debt-to-equity of 0.72.
Is Ortin Global Ltd a good investment?
Bull Run gives Ortin Global Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.